Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder that affects multiple systems of the body—particularly those controlling movement, balance, and vital autonomic functions such as blood pressure, heart rate, bladder control, and breathing.

MSA belongs to a group of conditions known as synucleinopathies, characterized by the abnormal accumulation of a protein called alpha-synuclein in brain cells. Unlike more common neurological diseases, MSA often presents with a complex combination of symptoms, making early diagnosis challenging and underscoring the urgent need for improved diagnostic tools.

Clinically, MSA is typically categorized into two subtypes:

MSA-P (parkinsonian type): dominated by stiffness, slowness, and tremor
MSA-C (cerebellar type): characterized by impaired coordination, balance, and speech

In both forms, autonomic failure—including severe drops in blood pressure upon standing (orthostatic hypotension)—is a defining feature.

The Urgency
MSA progresses more rapidly than many other neurodegenerative diseases. Most individuals experience increasing disability over time, often requiring mobility assistance and comprehensive care. While current treatments can help manage symptoms, there is no cure and no therapy that can yet slow or stop disease progression. This reality makes MSA one of the most urgent unmet needs in neurology today.